Turing CEO Martin Shkreli arrested by FBI, say reports

17 December 2015
fbi-seal-big

The chief executive and founder of Turing Pharmaceuticals Martin Shkreli has been arrested by the FBI on suspicion of fraud, according to reports.

The 32-year-old sparked outrage in September after he raised the price of Daraprim (pyrimethamine) – used to treat toxoplasmosis, a serious disease that affects AIDS patients and pregnant women and their babies – from $13.50 to $750 a pill.

Turing is one of four companies currently being investigated by the US Senate’s special committee on aging, after dramatically hiking the price of off-patent, life-saving drugs shortly after acquiring them.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight